Literature DB >> 2172396

An adenovirus recombinant that expresses the human cytomegalovirus major envelope glycoprotein and induces neutralizing antibodies.

G S Marshall1, R P Ricciardi, R F Rando, J Puck, R W Ge, S A Plotkin, E Gönczöl.   

Abstract

The gene of the human cytomegalovirus (HCMV) major envelope glycoprotein, gB, was cloned from the Towne strain and inserted into adenovirus type 5 downstream of the E3 promoter. The recombinant virus, Ad-gB, expressed antigenically related proteins of 58, 30, 25, and 23 kDa in A549 and MRC-5 cells; the 58-kDa protein had the same mobility as the native gB from HCMV-infected MRC-5 cells and virions. All four proteins were detected by a monospecific polyclonal antiserum and by a monoclonal antibody in immunoblot and immunofluorescence assays. Hamsters infected intranasally with live Ad-gB developed protein-specific and HCMV-neutralizing antibody. This study confirms the importance of gB in the generation of the neutralizing immune response to HCMV and demonstrates the potential of live adenoviruses as vaccine vectors.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2172396     DOI: 10.1093/infdis/162.5.1177

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

1.  Costimulatory protein B7-1 enhances the cytotoxic T cell response and antibody response to hepatitis B surface antigen.

Authors:  X S He; H S Chen; K Chu; M Rivkina; W S Robinson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

Review 2.  Prophylaxis of cytomegalovirus disease in high-risk patients.

Authors:  M Scholz; J Cinatl; H W Doerr
Journal:  Infection       Date:  1997 Sep-Oct       Impact factor: 3.553

3.  Studies on the stability of a human adenovirus-rabies recombinant vaccine.

Authors:  K K Kalicharran; V S Springthorpe; S A Sattar
Journal:  Can J Vet Res       Date:  1992-01       Impact factor: 1.310

4.  Stanley Plotkin: the bright spark of cytomegalovirus vaccines.

Authors:  Edward S Mocarski
Journal:  Med Microbiol Immunol       Date:  2015-03-20       Impact factor: 3.402

5.  Developing a Vaccine against Congenital Cytomegalovirus (CMV) Infection: What Have We Learned from Animal Models? Where Should We Go Next?

Authors:  Mark R Schleiss
Journal:  Future Virol       Date:  2013-12       Impact factor: 1.831

6.  Human cytomegalovirus US3 and UL36-38 immediate-early proteins regulate gene expression.

Authors:  A M Colberg-Poley; L D Santomenna; P P Harlow; P A Benfield; D J Tenney
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

Review 7.  Diagnosis and management of human cytomegalovirus infection in the mother, fetus, and newborn infant.

Authors:  Maria Grazia Revello; Giuseppe Gerna
Journal:  Clin Microbiol Rev       Date:  2002-10       Impact factor: 26.132

8.  Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus.

Authors:  Zhongde Wang; Corinna La Rosa; Rebecca Maas; Heang Ly; John Brewer; Shahram Mekhoubad; Pirouz Daftarian; Jeff Longmate; William J Britt; Don J Diamond
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

9.  Autoimmune response to U1 small nuclear ribonucleoprotein (U1 snRNP) associated with cytomegalovirus infection.

Authors:  M M Newkirk; W J van Venrooij; G S Marshall
Journal:  Arthritis Res       Date:  2001-04-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.